CML | Jotup

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Retrieved on:

tisdag, maj 14, 2024

BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the first quarter ended March 31, 2024, and provided a business update, including highlights of pipeline progress.

Key Points:

“The first quarter of 2024 was a pivotal quarter for Enliven.
Research and development (R&D) expenses: R&D expenses were $20.0 million for the first quarter of 2024, compared to $11.9 million for the first quarter of 2023.
General and administrative (G&A) expenses: G&A expenses for the first quarter of 2024 were $6.0 million, compared to $4.5 million for the first quarter of 2023.
Net Loss: Enliven reported a net loss of $22.7 million for the first quarter of 2024, compared to a net loss of $14.7 million for the first quarter of 2023.

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

Retrieved on:

tisdag, maj 14, 2024

Patient, MDS, Survival, CML, Risk, University, Congress, Recurrence, AML, EHA, Cancer, ALL, Graft-versus-host disease, Leukemia, Poster, Blood

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain.

Key Points:

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain.
“We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at the upcoming EHA congress,” said Trishna Goswami, M.D., Chief Medical Officer, IN8bio.
A copy of the poster presentation will be available at https://in8bio.com after the poster session begins.
For more information about the study, visit www.clinicaltrials.gov (NCT03533816).

Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib

Retrieved on:

torsdag, maj 23, 2024

Of those prescribed a PPI, 66% of the prescriptions were by a different healthcare provider.

Key Points:

Of those prescribed a PPI, 66% of the prescriptions were by a different healthcare provider.
Further, the presentation provides new information on the bioavailability of crystalline dasatinib when comedicated with a PPI, demonstrating a substantially higher than previously reported impact of PPIs on the bioavailability of crystalline dasatinib, with Cmax and AUC24 being reduced by 96% and 88% respectively.
“Consistent absorption and bioavailability of dasatinib are critical for adequate disease control and patient outcomes, this is however often overlooked in clinical practice as our data demonstrates,” said Per Andersson, CEO of Xspray.
Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability.

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on:

torsdag, maj 9, 2024

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.

Key Points:

(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.
“We continued to make significant progress advancing our gamma-delta T cell programs in the first quarter of 2024,” said William Ho, CEO and co-founder of IN8bio.
INB-100: Report updated interim results from the ongoing Phase 1 investigator-sponsored trial at the 2024 EHA Annual Meeting, held June 13-16 in Madrid, Spain.
INB-200: Report interim Phase 1 long-term follow up results in GBM at multiple medical meetings in 2024 including at the 2024 ASCO Annual Meeting.

Cousins Maine Lobster Celebrates Second Truck Launch In Maryland!

Retrieved on:

tisdag, maj 7, 2024

Restaurant, Multimedia, FDD, CML, Franchise disclosure document, Food

The expansion is led by brothers and franchisees, Yunus, and Thameem Shahul, who are in their 6th year franchising with Cousins Maine Lobster.

Key Points:

The expansion is led by brothers and franchisees, Yunus, and Thameem Shahul, who are in their 6th year franchising with Cousins Maine Lobster.
The Maryland truck marks the Shahul's 12th CML food truck to date.
Yunus Shahul shared, "We are elated to unveil our second food truck in Maryland, an exciting development that underscores our commitment to engaging with diverse communities across the state.
Cousins Maine Lobster has food trucks and restaurants across the U.S., with additional new units planned this year.

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Retrieved on:

torsdag, april 11, 2024

Patient, BCR, Safety, MMR, TKI, CML, Caregiver, Second generation, Therapy, Acute leukemia, Pharmaceutical industry

BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).

Key Points:

"Similar to our experience with previous successful Phase 1 trials in CML, ELVN-001 looks promising.
The preliminary data support that ELVN-001 is a potent and highly selective BCR::ABL1 inhibitor that has activity in heavily pre-treated patients, including post-asciminib patients."
“We are thrilled with ELVN-001’s initial Phase 1 data in heavily pre-treated patients with CML,” said Sam Kintz, Co-founder and Chief Executive Officer of Enliven.
The discussion will cover details of ELVN-001’s Phase 1 initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Retrieved on:

onsdag, april 10, 2024

University, Ipsen, Obesity, Novartis, IPO, Therapy, Pfizer, CML, Head, Biology, Biogen, Sangamo Therapeutics, Growth, Pharmaceutical industry

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.

Key Points:

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
“We are excited to welcome Melita to the Terns leadership team at a critical stage of growth at the company,” said Amy Burroughs, chief executive officer of Terns.
Most recently, she served as chief business officer at Structure Therapeutics, where she was responsible for the company’s business strategy, partnering initiatives, commercial planning, corporate branding and communications.
Previously, Ms. Jung served as senior vice president and head of business development at Sangamo Therapeutics, a genomic medicines company.

Cousins Maine Lobster Celebrates 12th Year Anniversary & 65th Unit Opening with Expansion into Northern Illinois!

Retrieved on:

tisdag, april 23, 2024

Restaurant, Multimedia, Food, FDD, CML, Franchise disclosure document

The expansion is led by brothers and franchisees, Yunus, and Thameem Shahul, who are in their 6th year franchising with Cousins Maine Lobster.

Key Points:

The expansion is led by brothers and franchisees, Yunus, and Thameem Shahul, who are in their 6th year franchising with Cousins Maine Lobster.
The Northern Illinois truck marks the Shahul's 11th CML food truck to date.
This represents a major achievement as we expand our outreach to engage with dynamic communities of suburban Chicago on a more consistent basis.
Cousins Maine Lobster has food trucks and restaurants across the U.S., with additional new units planned this year.

Cousins Maine Lobster Celebrates 12th Year Anniversary & 65th Unit Opening with Expansion into Rhode Island!

Retrieved on:

tisdag, april 23, 2024

Restaurant, Multimedia, FDD, Seafood, Learning, CML, Franchise disclosure document, Food

The new truck will service all of Rhode Island, as well as Windham and New London counties in eastern Connecticut.

Key Points:

The new truck will service all of Rhode Island, as well as Windham and New London counties in eastern Connecticut.
When asked about the expansion, Tara Nelson shared, "We can't wait to bring Cousins Maine Lobster to the Rhode Island market and beyond.
Cousins Maine Lobster is the perfect addition to the local food truck scene, and we are excited to serve all our hungry customers."
Cousins Maine Lobster has food trucks and restaurants across the U.S., with more than 20 new units planned in the coming year.

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Retrieved on:

tisdag, april 9, 2024

Acute leukemia, Canadian Aviation Regulations, Cell, CD33, AML, Patient, Tissue, CML, Acute myeloid leukemia, Leukemia, Death, AACR, Neoplasm, Cancer, Safety, CD123, Antigen, Vaccine

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.

Key Points:

The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue.
Approved CAR-T therapies have shown remarkable efficacy against B cell malignancies, offering hope to patients with limited treatment options.
“These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”